Details for Patent: 7,838,552

Which drugs does patent 7,838,552 protect, and when does it expire?

Patent 7,838,552 protects BYVALSON and is included in one NDA.

This patent has thirty-seven patent family members in fifteen countries.

Summary for Patent: 7,838,552

Title:	Compositions comprising nebivolol
Abstract:	Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
Inventor(s):	Davis; Eric (Morgantown, WV), O'Donnell; John P. (Morgantown, WV), Bottini; Peter Bruce (Morgantown, WV), Shaw; Andrew (Morgantown, WV), Mason; R. Preston (Manchester, MA)
Assignee:	Forest Laboratories Holdings Limited (BM)
Application Number:	11/273,992
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,838,552
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,838,552

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	BYVALSON	nebivolol hydrochloride; valsartan	TABLET;ORAL	206302-001	Jun 3, 2016		DISCN	Yes	No						METHOD OF TREATING HYPERTENSION

International Family Members for US Patent 7,838,552

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	2815
African Regional IP Organization (ARIPO)	2896
Austria	E509627